Successful trial of artificial pancreas may 'transform type 1 diabetes care'
A pioneering artificial pancreas has been hailed a success, after the first long-term test of its use by patients.
The device improved the amount of time patients spent overnight with blood sugar in the ideal range by 13.5%.
A group of 24 adults with type 1 diabetes used the machine each night for four weeks in their own homes.
“There is now real hope that this technology had the potential to transform the lives of people with type 1 diabetes within a generation”
It was the first time in the world that such a device has been used for more than a couple of days without medical supervision.
The artificial pancreas is worn outside the body and linked to a glucose sensor under the skin.
Blood sugar levels are measured and the information transmitted to an insulin pump, which releases just the right amount of the hormone into the body.
Participants in the study, funded by the charity Diabetes UK, switched on the device after their evening meal and turned it off again before breakfast the next morning.
Every 12 minutes, the software adjusted the amount of insulin administered by the pump.
Lead researcher Dr Roman Hovorka, from Cambridge University, said: “The advantage of a ‘closed-loop’ system like this one is the ability to fine tune insulin delivery to account for variations in overnight insulin needs.
“The system was able to adapt and safely cope with these variations to achieve more consistent glucose control. Now that we’ve tested the system at multiple centres, we can see that its benefits apply to a wide range of individuals.
“A large-scale clinical trial of the artificial pancreas will now be the next step in helping to translate these exciting findings into an end product that will help to transform the management of type 1 diabetes by achieving consistent glucose levels and reducing the risk of blood glucose levels falling dangerously low during the night. Such a product may be viable with existing technology.”
Around 300,000 people in the UK suffer from type 1 diabetes, which is an autoimmune disease.
Findings from the study were presented at the American Diabetes Association’s annual meeting in San Francisco and published in journal The Lancet Diabetes & Endocrinology.
Dr Alasdair Rankin, director of research at Diabetes UK, said: “These results are hugely exciting, as they represent a significant step towards an artificial pancreas that can be used independently at home as a routine treatment option.
“Though more work will be needed before this happens, there is now real hope that this technology had the potential to transform the lives of people with type 1 diabetes within a generation.
“The potential health benefits of this could be enormous. At the moment, people with type 1 diabetes are over twice as likely to die in any given year as someone of the same age who does not have the condition. That is a tragic reality that the artificial pancreas has the potential to change.”